Wire · opportunities
Insilico Medicine Convenes O3DC, an Open Consortium for Benchmark Quality in AI-Driven ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
Insilico Medicine launched the Open Drug Discovery and Development Consortium (O3DC), providing a community-curated index of AI-driven drug discovery benchmarks that highlights each benchmark's limitations and biases to improve evaluation standards in computational drug discovery.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
You now have transparent access to detailed AI drug discovery benchmark flaws and critiques in one place. If you develop AI-driven pharma tools, this opens a new route to prove your model’s real-world value beyond superficial benchmark scores.
◆ Coverage
1 source · 24 Aug 2026
◆ Related on Wire
◆ Topics